,for, Item ID-
  • #1205936
  • AbbVie Inc #00074231030

RINVOQ® Upadacitinib 30 mg Tablet 30 Tablets

RINVOQ ER, TAB 30MG (30/EA)

No Image

Features

  • RINVOQ® (upadacitinib) a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable
  • More …
Strength
15 mg 30 mg
  Log In to Order
or

Product Specifications


Features
  • RINVOQ® (upadacitinib) a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable

Professionals Also Viewed